Quanterix (QTRX) M&A Announcement summary

Deal rationale and strategic fit

• Creates the first integrated platform for ultra-sensitive detection of blood and tissue-based protein biomarkers, combining Quanterix's neurology leadership with Akoya's spatial biology expertise to accelerate biomarker translation from research to clinic.

• Expands technology offerings and addressable market to $5 billion, targeting high-growth segments in neurology, oncology, and immunology.

• Enables cross-selling opportunities and a broader continuum of solutions for biomarker discovery and diagnostics, leveraging a combined installed base of 2,300 instruments.

• Supports a strategic plan focused on menu expansion, adjacency growth, and translational diagnostics, especially in Alzheimer's disease.

• Positions the combined company to accelerate development of new liquid biopsy tests and companion diagnostics.

Financial terms and conditions

• All-stock transaction: Akoya shareholders receive 0.318 Quanterix shares per Akoya share, a 19% premium to Akoya's unaffected price on Nov 14, 2024.

• Quanterix shareholders will own approximately 70% and Akoya shareholders 30% of the combined entity on a fully diluted basis.

• Combined company expects approximately $175 million in cash and no debt at closing, after transaction costs and debt repayment.

• Combined revenue of $220 million (TTM ended Q3 2024).

• Transaction expected to close in Q2 2025, pending shareholder and regulatory approvals.

Synergies and expected cost savings

• Anticipated $40 million in annual cost synergies by end of 2026, with $20 million realized in the first year post-close.

• Synergies to be achieved through commercial infrastructure consolidation, operational efficiencies, and streamlining corporate functions.

• Integration of commercial teams and facilities, leveraging overlapping geographies and customer bases.

• Path to positive free cash flow generation in 2026, accelerated by combined cost initiatives.

• Cost savings from eliminating duplicative structures and combined reagent manufacturing.